Lupus & antiphospholipid syndrome
Unveiling the role of TLR9 promoter variants in susceptibility and clinical features of systemic lupus erythematosus
Authors' conclusion
Our data suggest that promoter variation in TLR9, specifically the rs5743836 C allele and the combined rs187084-rs5743836 CC haplotype, is linked to an increased risk of SLE and more disease activity and severe clinical presentation.
Study context
- Population
- Iranian population: SLE patients and age- and sex-matched healthy controls
- Participants
- 140 vs 140
- Comparison
- SLE patients vs healthy controls: TLR9 promoter SNPs rs187084 and rs5743836 and their haplotypes
- SLEn = 140
- Healthy controlsn = 140reference
- Outcome
- Association of TLR9 promoter SNPs (rs187084, rs5743836) and their haplotypes with SLE risk and clinical/laboratory features
Methodological detailsage- and sex-matched healthy controls, real-time PCR-high resolution melting (PCR-HRM) genotyping
- Age- and sex-matched healthy controls
- Real-time PCR-HRM genotyping
Main finding
As reported in the abstract
SLE risk by TLR9 promoter genotype
- rs5743836 CC and CT genotypes and C allele associated with increased SLE risk
- P < 0.05
- No association between rs187084 and SLE risk
- P > 0.05
- Combined rs187084-rs5743836 CC haplotype associated with increased SLE risk (CC vs TT haplotype)
- P < 0.001
Observational data: associations, not effects.
Further findings
Clinical features in SLE patients carrying the C allele in both promoter variants
- Earlier disease onset and more active and severe disease: higher C-reactive protein (CRP) and anti-dsDNA, reduced C3 and C4, more renal and neurological complications
- P < 0.05
Original publication
Unveiling the role of TLR9 promoter variants in susceptibility and clinical features of systemic lupus erythematosus. Lupus. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →